Search Within

Population Sciences Research Program

  1. "Nursing"
  2. "Center for Hematologic Malignancies"
  3. "Sloan Kettering Institute Postdocs"
  4. "Caleb Ho"
Formats
  1. Journal Article (2)
  2. Meeting Abstract (2)
  3. Research Letter (1)
Groups
  1. Biostatistics Service (5)
  2. Bone Marrow Transplant (5)
  3. CTCR Scholars (5)
  4. Center for Hematologic Malignancies (5)
  5. Department of Medicine (5)
  6. Epidemiology and Biostatistics (5)

More Groups

People
  1. Caleb Ho (5)
  2. Gunjan Shah (5)
  3. Michael Scordo (5)
  4. Ahmet Dogan (4)
  5. Alexander Lesokhin (4)
  6. Andriy Derkach (4)

More People

Years
  1. 2021 (2)
  2. 2020 (3)
Publications
  1. Blood (2)
  2. American Journal of Hematology (1)
  3. Blood Advances (1)
  4. JAMA Oncology (1)
Publishers
  1. American Society of Hematology (3)
  2. American Medical Association (1)
  3. John Wiley & Sons, Inc. (1)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Research Letter

    Korde, N.; Mastey, D.; Tavitian, E.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Shah, U.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies
    Journal Article

    Sermer, D.; Batlevi, C.; Lia Palomba, M.; Shah, G.; Lin, R. J.; Perales, M. A.; Scordo, M.; Dahi, P.; Pennisi, M.; Afuye, A.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save